Although the method of cure is currently not available for AIDS, there is no vaccination available. However, this dilemma is now expected to be relieved.

According to foreign media reports, recently, the US Food and Drug Administration (FDA) announced that drugs in the world can have long-term reducing HIV infection risk have been approved.

The report pointed out that this injection drug is named "apretude", which will provide new alternatives to the exposure prevention (PREP) drugs such as Truvada and Destin (PREP) drugs.

Compared with Shuvai and Dacout, "apretude" does not need to be used daily, just in the first two months of the first use once, then only need to be injected every two months.

For the effects and security of "Apretude", the FDA announced two trials. Test 1 tested 4,566 orchestral men and across sex women; Test 2 included 3,224 funny women.

Two groups were divided into two groups in two trials, and a group took Shu Dai; and a group took Cabotegravir daily while using Apretude.

The results show that the risk of the subject infected with HIV infected with HIV was reduced by 69% compared to the subject takes Shuvai, and the risk of the subject infected with HIV was reduced by 90%.

However, the drug also uses restrictions, only adults and teenagers used in 35 kg and or more, and HIV detection is negative at the beginning of use. If HIV detects positive patients, it may cause side effects of drug resistance.